Clinical phenotype/genetic background | FTD total, N = 254 | FTD-TDP, N = 64 | FTD-tau, N = 27 | HC, N = 105 |
---|---|---|---|---|
bvFTD (N) | 125 | 37 | 3 | – |
C9-HRE (N) | 18 | 18 | 0 | – |
GRN (N) | 18 | 18 | 0 | – |
MAPT (N) | 2 | 0 | 2 | – |
nfvPPA (N) | 63 | 18 | 0 | – |
C9-HRE (N) | 5 | 5 | 0 | – |
GRN (N) | 13 | 13 | 0 | – |
MAPT (N) | 0 | 0 | 0 | – |
svPPA (N) | 33 | 0 | 0 | – |
C9-HRE (N) | 0 | 0 | 0 | – |
GRN (N) | 0 | 0 | 0 | – |
MAPT (N) | 0 | 0 | 0 | – |
PSP (N) | 24 | 0 | 24 | – |
C9-HRE (N) | 0 | 0 | 0 | – |
GRN (N) | 0 | 0 | 0 | – |
MAPT (N) | 1 | 0 | 1 | – |
FTD-MND (N) | 9 | 9 | 0 | – |
C9-HRE (N) | 3 | 3 | 0 | – |
GRN (N) | 0 | 0 | 0 | – |
MAPT (N) | 0 | 0 | 0 | – |
Gender, female % | 52% | 52% | 44% | 56% |
Age, years, mean (SD) | 66.1 (9.0) | 62.2 (9.2) | 69.0 (10.5) | 67.2 (9.8) |
FTD-CDR Sum of Boxes, mean (SD) | 6.2 (4.4) | 7.5 (4.7) | 4.2 (3.0) | – |
Serum TDP-43, pg/mL, median (interquartile range, IQR) | 204.8* (247.8) | 190.3#,^ (222.6) | 305.8^ (290.3) | 253.1*,# (258.8) |